They may provide more convenience and improved adherence for some patients
Traditional GLP-1 drugs such as semaglutide are peptide-based molecules that can be broken down by stomach acid and digestive enzymes before they reach the bloodstream
While body weight and metabolic phenotypes remain the primary endpoints, the outcome spectrum is progressively extending toward lipotoxic load [e.g., hepatic fat and visceral adipose tissue (VAT)], inflammatory/cardiometabolic risk markers, and reproductive outcomes with higher clinical decision-making value, such as menstruation, ovulation, and pregnancy
The most frequently reported downsides include: In clinical practice, these side effects are usually transient (meaning they go away on their own as your body adapts)
Ozempic is FDA approved for type 2 diabetes, while Wegovy is approved for chronic weight management